Back

CIRRUS­HCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Hottest trials and trial updates (2) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Anjali Owens

University of Pennsylvania, Philadelphia (United States of America)

20 More presentations in this session

Presentation thumbnail
DIGIT­HF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction
Professor U. Bavendiek (Hannover, DE)
Slides Video
Presentation thumbnail
Discussant review - DIGIT­HF
Professor D. van Veldhuisen (Groningen, NL)
Slides Video
Presentation thumbnail
Panel discussion - DIGIT­HF
Video
Presentation thumbnail
Discussant review - CIRRUS­HCM
Professor I. Olivotto (Florence, IT)
Slides Video
Presentation thumbnail
Panel discussion - CIRRUS­HCM
Video

Access the full session

Session thumbnail
Hottest trials and trial updates (2)
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Discussant review - CIRRUS­HCM
thumbnail
Congress Presentation
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
thumbnail
Congress Presentation
Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A pre-specified analysis of MAPLE-HCM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources